{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:49Z","timestamp":1788869389979,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005969","name":"University of Bologna","doi-asserted-by":"publisher","award":["RFO2025"],"award-info":[{"award-number":["RFO2025"]}],"id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]},{"award":["RFO2025"],"award-info":[{"award-number":["RFO2025"]}],"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Progetto ALICE ONLUS\u2014Associazione per la lotta alla SEU","award":["2025"],"award-info":[{"award-number":["2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Childhood infections by Shiga toxin (Stx)-producing Escherichia coli (STEC) cause bloody diarrhea and the life-threatening hemolytic-uremic syndrome (HUS). Stx2, produced by STEC in the gut, is released into the bloodstream and interacts with circulating cells (monocytes, neutrophils, and platelets) through two different receptors: Gb3Cer (globotriaosylceramide) and Toll-like receptor 4 (TLR4). Consequently, blood cells form leukocyte\/platelet aggregates and release pathogenic Stx2-containing extracellular vesicles (EVs) that, by damaging the kidney, induce the transition from bloody diarrhea to HUS. Human blood was incubated with Stx2 to induce the formation of neutrophil\/platelet and platelet-only aggregates (observed in May\u2013Gr\u00fcnwald Giemsa-stained blood smears) and pathogenic blood cell\u2013derived EVs (isolated by size-exclusion chromatography or differential centrifugation) toxic to Vero cells (assessed by a viability assay). In the presence of a monoclonal antibody against TLR4 (anti-TLR4), the formation of neutrophil\/platelet and platelet-only aggregates was greatly reduced compared to treatment with Stx2 alone. Moreover, anti-TLR4 significantly decreased the total mass of pathogenic blood cell\u2013derived EVs produced by Stx2 (detected by nanoparticle tracking analysis), which proved less toxic to Vero cells than those produced by Stx2 alone. The impairment of the Stx2-TLR4 axis obtained during the experimental pathogenesis of HUS provides proof-of-concept evidence supporting TLR4 as a potential therapeutic target.<\/jats:p>","DOI":"10.3390\/ijms27187992","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:23:51Z","timestamp":1788866631000},"page":"7992","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome"],"prefix":"10.3390","volume":"27","author":[{"given":"Elisa","family":"Varrone","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"given":"Veronica","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Gianluca","family":"Storci","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-6551","authenticated-orcid":false,"given":"Massimiliano","family":"Bonaf\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy"},{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-905X","authenticated-orcid":false,"given":"Barbara","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Ozzano dell\u2019Emilia, 40064 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-744X","authenticated-orcid":false,"given":"Maurizio","family":"Brigotti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMra2108739","article-title":"Shiga Toxin-Producing Escherichia coli and the Hemolytic-Uremic Syndrome","volume":"389","author":"Freedman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ajpath.2021.02.011","article-title":"Extracellular Vesicles and Renal Endothelial Cells: A Fatal Attraction in Hemolytic Uremic Syndrome","volume":"191","author":"Varrone","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_3","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.11.3.450","article-title":"Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections","volume":"11","author":"Paton","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1086\/338115","article-title":"Escherichia coli harboring Shiga toxin 2 gene variants: Frequency and association with clinical symptoms","volume":"185","author":"Friedrich","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1086\/501472","article-title":"Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: Therapeutic implications for hemolytic-uremic syndrome","volume":"193","author":"Armstrong","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41576","DOI":"10.1074\/jbc.M107819200","article-title":"Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood","volume":"276","author":"Kimura","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1128\/IAI.71.10.6075-6078.2003","article-title":"Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer","volume":"71","author":"Marcato","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00018-012-1060-z","article-title":"Facing glycosphingolipid-Shiga toxin interaction: Dire straits for endothelial cells of the human vasculature","volume":"70","author":"Bauwens","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/joim.12546","article-title":"Haemolytic uraemic syndrome","volume":"281","author":"Karpman","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"St\u00e5hl, A.L., Arvidsson, I., Johansson, K.E., Chromek, M., Rebetz, J., Loos, S., Kristoffersson, A.C., B\u00e9k\u00e1ssy, Z.D., M\u00f6rgelin, M., and Karpman, D. (2015). A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004619"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Stahl, A.L., Sartz, L., Nelsson, A., Bekassy, Z.D., and Karpman, D. (2009). Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006990"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0039-3400301","article-title":"Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children","volume":"120","author":"Brigotti","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Valles, P.G., Gil Lorenzo, A.F., Garcia, R.D., Cacciamani, V., Benardon, M.E., and Costantino, V.V. (2023). Toll-like Receptor 4 in Acute Kidney Injury. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021415"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vaure, C., and Liu, Y. (2014). A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00316"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Crammond, P., Hastak, P., Delaney, A., and Sasson, S.C. (2026). Taking its TOLL: The role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1761361"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00467-011-2014-7","article-title":"Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome","volume":"27","author":"Valles","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s40364-024-00700-y","article-title":"Platelet signaling in immune landscape: Comprehensive mechanism and clinical therapy","volume":"12","author":"Yan","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40364-024-00639-0","article-title":"Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment","volume":"12","author":"Zhuang","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Varrone, E., Consagra, L., Rossi, G., Carnicelli, D., Paterini, P., Brunetti, B., Ricci, F., Tazzari, P.L., Storci, G., and Bonafe, M. (2026). Shiga Toxin 1a Blunts Shiga Toxin 2a-pathogenic Effects in Blood. Thromb. Haemost.","DOI":"10.1055\/a-2805-9903"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Celi, A.B., Goldstein, J., Rosato-Siri, M.V., and Pinto, A. (2022). Role of Globotriaosylceramide in Physiology and Pathology. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.813637"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.peptides.2017.03.002","article-title":"Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity","volume":"91","author":"Vaara","year":"2017","journal-title":"Peptides"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113076","DOI":"10.1016\/j.isci.2025.113076","article-title":"An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndrome","volume":"28","author":"Varrone","year":"2025","journal-title":"iScience"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.4049\/jimmunol.1500671","article-title":"The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils","volume":"196","author":"Carnicelli","year":"2016","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ijmm.2018.06.013","article-title":"Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome","volume":"308","author":"Brigotti","year":"2018","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"172975","DOI":"10.1016\/j.ejphar.2020.172975","article-title":"Toll-like receptor 4: A promising crossroads in the diagnosis and treatment of several pathologies","volume":"874","author":"Garcia","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115338","DOI":"10.1016\/j.biopha.2023.115338","article-title":"Toll-like receptor 4: A potential therapeutic target for multiple human diseases","volume":"166","author":"Wei","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"114291","DOI":"10.1016\/j.ejmech.2022.114291","article-title":"Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective","volume":"235","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/annrheumdis-2019-216487","article-title":"Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: A phase II study","volume":"79","author":"Monnet","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood-2002-10-3301","article-title":"Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells","volume":"102","author":"Matussek","year":"2003","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/7992\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:26:22Z","timestamp":1788866782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/7992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":30,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27187992"],"URL":"https:\/\/doi.org\/10.3390\/ijms27187992","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}